Efrain Weintraub Ben Zion

Dr. Efrain Weintraub Ben Zion

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
GMGerman Rivera Monroy
German Rivera Monroy
RPRenata Murguiondo Pérez
Renata Murguiondo Pérez
EZEfrain Weintraub Ben Zion
Efrain Weintraub Ben Zion
OAOscar Vidal Alcántar-Garibay
Oscar Vidal Alcántar-Garibay
ELEricka Cristina Loza-López
Ericka Cristina Loza-López
Antonio IbarraAntonio Ibarra
Antonio Ibarra
Neurodegenerative diseases (NDDs) are a major health problem worldwide. Statistics suggest that in America in 2030 there will be more than 12 million people suffering from a neurodegenerative pathology. Furthermore, the increase in life expectancy enhances the importance of finding new and better therapies for these pathologies. NDDs could be classified into chronic or acute, depending on the time required for the development of clinical symptoms and brain degeneration. Nevertheless, both chronic and acute stages share a common immune and inflammatory pathway in their pathophysiology. Immunization with neural-derived peptides (INDP) is a novel therapy that has been studied during the last decade. By inoculating neural-derived peptides obtained from the central nervous system (CNS), this therapy aims to boost protective autoimmunity, an autoreactive response that leads to a protective phenotype that produces a healing environment and neuroregeneration instead of causing damage. INDP has shown promising findings in studies performed either in vitro, in vivo or even in some pre-clinical trials of different NDDs, standing as a potentially beneficial therapy. In this review, we will describe some of the studies in which the effect of INDP strategies have been explored in different (chronic and acute) neurodegenerative diseases.

9 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MGMario Galindo-Méndez
Mario Galindo-Méndez
MGMario Galindo-Ruiz
Mario Galindo-Ruiz
MCMaría Florencia Concheso-Venegas
María Florencia Concheso-Venegas
SMSebastián Uriel Mendoza Molina
Sebastián Uriel Mendoza Molina
DCDavid Orozco Cruz
David Orozco Cruz
EZEfrain Weintraub Ben Zion
Efrain Weintraub Ben Zion
Since its discovery, vitamin D (VD) has been known for its implications in maintaining bone homeostasis. However, in recent years it has been discovered that the vitamin D receptor is expressed on different cells of the immune system and that these cells can locally produce the active form of this molecule, calcitriol, strongly suggesting that this vitamin might play a key role in both branches of the immune system, innate and adaptive. Recent evidence has demonstrated that VD participates in the different protective phases of the immune system against invading microorganisms, including in the activation and production of antimicrobial peptides, in the inactivation of replication of infectious agents, in the prevention of the exposure of cellular receptors to microbial adhesion, and, more importantly, in the modulation of the inflammatory response. In recent years, the world has witnessed major outbreaks of an ancient infectious disease, dengue fever; the emergence of a pandemic caused by an unknown virus, SARS-CoV-2; and the resurgence of a common respiratory infection, influenza. Despite belonging to different viral families, the etiological agents of these infections present a common trait: their capacity to cause complications not only through their cytopathic effect on target tissues but also through the excessive inflammatory response produced by the human host against an infection. This review outlines the current understanding of the role that vitamin D plays in the prevention of the aforementioned diseases and in the development of their complications through its active participation as a major modulator of the immune response.